CCO Independent Conference Coverage of IDWeek 2022: Clinical Impact of New COVID-19 Data*

Many interesting COVID-19 presentations were delivered at IDWeek 2022, but I found 2 studies particularly relevant for clinical practice—an analysis of risk factors for severe breakthrough infections and a secondary endpoint analysis of the randomized EPIC-HR study in those at high risk for severe disease.

Gregory Huhn, MD, MPHTM Released: November 17, 2022

COVID-19 continued to be a major focus at IDWeek 2022, with research investigating many facets of infection, including 4 studies that I found particularly interesting—analyses of baricitinib or tocilizumab for severe COVID-19, inhaled interferon beta-1a for moderate COVID-19, and tixagevimab plus cilgavimab for pre-exposure prophylaxis in immunocompromised individuals, and outcomes among adult solid organ transplant recipients with COVID-19–associated fungal infections.

Cristina Mussini, MD Released: November 17, 2022

Read expert faculty member summaries of the latest data on COVID-19 vaccines, risk factors and risk stratification, diagnostics, therapeutics, treatment of patients with immunocompromise, and long COVID.

Gregory Huhn, MD, MPHTM Princy N. Kumar, MD, FIDSA, MACP Cristina Mussini, MD Paul E. Sax, MD Released: November 1, 2022

Listen to expert insights on updates and new COVID-19 data from IDWeek 2022, including data on vaccines, risk factors and risk stratification, diagnostics, therapeutics, treatment of patients with immunocompromise, and long COVID.

Gregory Huhn, MD, MPHTM Cristina Mussini, MD Released: November 8, 2022

Listen to expert insights on updates and new COVID-19 data from IDWeek 2022, including data on vaccines, risk factors and risk stratification, diagnostics, therapeutics, treatment of patients with immunocompromise, and long COVID.

Princy N. Kumar, MD, FIDSA, MACP Paul E. Sax, MD Released: November 14, 2022

Listen to expert insights from Princy N. Kumar, MD, and Paul E. Sax, MD, on updates and new COVID-19 data from IDWeek 2022, including data on vaccines, risk factors and risk stratification, diagnostics, therapeutics, treatment of patients with immunocompromise, and long COVID.

Princy N. Kumar, MD, FIDSA, MACP Paul E. Sax, MD Released: November 18, 2022